Pregled bibliografske jedinice broj: 450537
Multidrug resistance-associated P-glycoprotein phenotype impact on treatment response in B-CLL
Multidrug resistance-associated P-glycoprotein phenotype impact on treatment response in B-CLL // Haematologica 84 (EHA-4 Abstract Book)
Barcelona, Španjolska, 1999. str. 231-231 (poster, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 450537 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Multidrug resistance-associated P-glycoprotein phenotype impact on treatment response in B-CLL
Autori
Svoboda-Beusan, Ivna ; Bendelja, Krešo ; Kušec, Rajko ; Pejša, Vlatko ; Jakšić, Branimir ; Vitale, Branko
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Haematologica 84 (EHA-4 Abstract Book)
/ - , 1999, 231-231
Skup
4th Congress of the European Haematology Association
Mjesto i datum
Barcelona, Španjolska, 09.06.1999. - 11.06.1999
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
MDR; B-CLL; Pgp phenotype
Sažetak
Objective: The relevance of P-glycoprotein (Pgp), a marker of multidrug resistance (MDR) in B-CLL is controversial. The aim of our study was to investigate whether the MDR status at diagnosis correlates with the clinical data (modified Rai, total tumour mass (TM), total lymphocyte count (TLC) and therapy outcome. Design and Methods: Study population consisted of 42 patients (25 males, 17 females with a mean age 62±12 yrs). Expression of Pgp was analyzed on flow cytometer using two mAbs against intracellular (C-219) and extracellular (MRK-16) Pgp epitope. As, due to low Pgp expression, percent of Pgp+ cells is not an adequate value, therefore Pgp level was calculated as a ratio of mean fluorescence (Pgp specific/isotypic control, RMF) where RMF>1, 5 is considered as positive. Results: in 31 non-treated B-CLL patients elevated RMF (median C-219=3, 11 and MRK-16=2, 88) was found, with no correlation to TLC, TTM or modified Rai. We monitored patients who underwent chemotherapy with MDR-independent drugs (chlorambucil or purine analogs). Patients responding to therapy (complete or partial remission) had significant decrease of both C-219 and MRK-16 Pgp-RMFs (medians 6, 78 to 2, 43 and 3, 0 to 1, 35, respectively). The non-responders had unchanged or increased Pgp-RMF. Conclusions: Our data indicate the importance of MDR monitoring in an attempt to treat resistant B-CLL patients with MDR-related drugs.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
0021001
Ustanove:
Imunološki zavod d.d.
Profili:
Branimir Jakšić
(autor)
Branko Vitale
(autor)
Krešo Bendelja
(autor)
Vlatko Pejša
(autor)
Ivna Svoboda-Beusan
(autor)
Rajko Kušec
(autor)